

# Stéphane Ducassou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1310155/publications.pdf>

Version: 2024-02-01

18  
papers

422  
citations

759233

12  
h-index

794594

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

742  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-dose (4.5 mg/m <sup>2</sup> ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 373-381.	2.5	9
2	Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias. <i>Blood</i> , 2022, 140, 253-261.	1.4	6
3	Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. <i>Journal of Pediatrics</i> , 2021, 231, 223-230.	1.8	1
4	Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcS@-ESMART Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3546-3560.	1.6	17
5	Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28032.	1.5	17
6	Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. <i>British Journal of Haematology</i> , 2020, 188, 170-173.	2.5	6
7	Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. <i>British Journal of Haematology</i> , 2020, 189, 931-942.	2.5	12
8	Genotype/phenotype correlations of childhood-onset congenital sideroblastic anaemia in a European cohort. <i>British Journal of Haematology</i> , 2019, 187, 530-542.	2.5	18
9	Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. <i>Blood</i> , 2019, 134, 9-21.	1.4	102
10	Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27571.	1.5	13
11	Maintenance Therapy With Interleukin-2 for Childhood AML. <i>HemaSphere</i> , 2018, 2, e159.	2.7	18
12	MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors. <i>Journal of Pathology</i> , 2017, 242, 347-357.	4.5	10
13	Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. <i>British Journal of Haematology</i> , 2017, 177, 751-758.	2.5	24
14	Impact of shared care program in follow-up of childhood cancer survivors: An intervention study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26541.	1.5	17
15	Impact of therapy in a cohort of unselected children with Down Syndrome-associated Acute Lymphoblastic Leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 983-985.	2.5	4
16	Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort). <i>International Journal of Epidemiology</i> , 2015, 44, 49-57.	1.9	60
17	Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. <i>British Journal of Haematology</i> , 2014, 164, 266-271.	2.5	31
18	Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Long-term follow-up from the French national cohort. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1759-1765.	1.5	35